alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. estimated glomerular filtration rate (egfr) <30ml/min pregnancy or breast feeding anticipated discharge in the next 72 hours allergy to study medication uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) shock or hypotension at the time of enrollment neutrophil count <1000/microliter concern for bacterial or fungal sepsis received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6) received a live vaccine the last 4 weeks those who were cognitively impaired or mentally disabled prior to covid diagnosis participation in another clinical trial for the treatment of covid-19.

alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. estimated glomerular filtration rate (egfr) <30ml/min pregnancy or breast feeding anticipated discharge in the next 72 hours allergy to study medication uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) shock or hypotension at the time of enrollment neutrophil count <1000/microliter concern for bacterial or fungal sepsis received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6) received a live vaccine the last 4 weeks those who were cognitively impaired or mentally disabled prior to covid diagnosis participation in another clinical trial for the treatment of covid-19.

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis 13. participation in another clinical trial for the treatment of covid-19.

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis 13. participation in another clinical trial for the treatment of covid-19.

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6), or b-cell depleting antibody in the prior 6 months (rituximab, other anti-cd20 mab) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis 13. participation in another clinical trial for the treatment of covid-19.

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6), or b-cell depleting antibody in the prior 6 months (rituximab, other anti-cd20 mab) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis 13. participation in another clinical trial for the treatment of covid-19.

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6), or b-cell depleting antibody in the prior 6 months (rituximab, other anti-cd20 mab) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis

1. alt or ast > 5 times the upper limit of normal (uln) or alt or ast >= 3 x uln and total bilirubin > 2 x uln. 2. estimated glomerular filtration rate (egfr) <30ml/min 3. pregnancy or breast feeding 4. anticipated discharge in the next 72 hours 5. allergy to study medication 6. uncontrolled hypertension (systolic blood pressure >160mmhg or diastolic blood pressure >100mmhg) 7. shock or hypotension at the time of enrollment 8. neutrophil count <1000/microliter 9. concern for bacterial or fungal sepsis 10. received immunomodulatory treatment within 30 days prior to enrollment e.g., bruton's tyrosine kinase/phosphoinositide 3 kinase/janus kinase inhibitor or cytokine-targeting biologic therapy (anti-tnf, il-6), or b-cell depleting antibody in the prior 6 months (rituximab, other anti-cd20 mab) 11. received a live vaccine the last 4 weeks 12. those who were cognitively impaired or mentally disabled prior to covid diagnosis